Cook A S, Webster B W, Terranova P F, Keel B A
Department of Obstetrics and Gynecology, University of Kansas School of Medicine, Wichita 67214.
Fertil Steril. 1988 Apr;49(4):704-12.
Lot differences in the biopotency of human menopausal gonadotropin (hMG) were evaluated and the potential biochemical basis was investigated. The in vivo biopotency of hMG was assessed by a unique bioassay that evaluates the number of ova shed in the cyclic hamster in response to hMG administration. Significant variation in hMG lots was observed using this assay. When subjected to chromatofocusing, hMG displayed five immunoreactive follicle-stimulating hormone (FSH) isohormones and nine luteinizing hormone (LH) isohormones. The relative distribution of FSH, but not LH isohormones, was slightly but significantly different between the lots tested. These data indicate that significant differences exist in the ability of commercially available hMG to stimulate follicular development and ovulation. The biochemical basis for these differences in in vivo biopotency remains to be elucidated.
评估了人绝经期促性腺激素（hMG）生物活性的批次差异，并研究了其潜在的生化基础。hMG的体内生物活性通过一种独特的生物测定法进行评估，该方法评估给予hMG后周期性仓鼠排出的卵子数量。使用该测定法观察到hMG批次存在显著差异。经色谱聚焦分析，hMG显示出五种免疫反应性促卵泡激素（FSH）同工激素和九种促黄体生成素（LH）同工激素。所测试批次之间FSH同工激素的相对分布略有但显著差异，而LH同工激素则无此差异。这些数据表明，市售hMG刺激卵泡发育和排卵的能力存在显著差异。这些体内生物活性差异的生化基础仍有待阐明。
